8-K: Xilio Therapeutics Faces Dual Nasdaq Delisting Threats

Xilio Therapeutics, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $10 million stockholders' equity requirement, adding to an existing minimum bid price non-compliance.

Summary

• Xilio Therapeutics, Inc. (the "Company") received a deficiency letter from the Nasdaq Stock Market, LLC on August 22, 2025.
• The letter notified the Company of non-compliance with Nasdaq Listing Rule 5450(b)(1)(A), which requires a minimum of $10.0 million in stockholders' equity.
• As of June 30, 2025, the Company reported stockholders' equity of $7,069,000 in its Quarterly Report on Form 10-Q.
• This deficiency has no immediate effect on the listing of the Company's common stock.
• The Company has 45 calendar days, until October 6, 2025, to submit a plan to regain compliance with the stockholders' equity requirement.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the letter.
• Alternatively, the Company may apply to transfer its securities to The Nasdaq Capital Market, provided it meets those listing requirements.
• Previously, on April 4, 2025, the Company received a deficiency letter for failing to maintain the $1.00 minimum bid price, as required by Nasdaq Listing Rule 5450(a)(1).
• The initial 180-day period to regain compliance with the minimum bid price requirement expires on October 1, 2025.
• As of August 22, 2025, the Company remains out of compliance with the Minimum Bid Price Requirement.
• The Company is continuing to evaluate available options to regain compliance with all Nasdaq listing requirements.

Sentiment

Score: 2

Explanation: The filing indicates significant financial and operational challenges, with the company facing two separate Nasdaq non-compliance issues (stockholders' equity and minimum bid price), increasing the risk of delisting. This suggests a very negative outlook.

Negatives

• Received a Nasdaq deficiency letter for failing to maintain a minimum of $10.0 million in stockholders' equity, reporting only $7,069,000 as of June 30, 2025.
• Remains out of compliance with the Nasdaq $1.00 minimum bid price requirement, initially notified on April 4, 2025.
• Faces potential delisting from The Nasdaq Global Select Market if compliance is not regained for both deficiencies.

Risks

• Potential delisting from The Nasdaq Global Select Market due to non-compliance with both the minimum stockholders' equity and minimum bid price requirements.
• Inability to regain compliance with Nasdaq listing rules within the specified deadlines, leading to a transfer to a lower market or full delisting.
• Uncertainty regarding the Company's ability to develop and execute a successful compliance plan for both deficiencies.
• Negative impact on investor confidence and access to capital due to ongoing listing non-compliance issues.

Future Outlook

The Company is evaluating available options to regain compliance with Nasdaq listing requirements, including submitting a plan for stockholders' equity and potentially transferring to The Nasdaq Capital Market, while also addressing the ongoing minimum bid price non-compliance.

Management Comments

• The Company is continuing to evaluate available options to regain compliance with the Nasdaq listing requirements.

Industry Context

This situation highlights the significant challenges faced by smaller biotechnology companies, particularly those in clinical development stages, in maintaining sufficient capital and market valuation to meet stringent exchange listing requirements. Non-compliance with listing rules can impact investor confidence and access to capital, which is critical for R&D-intensive sectors like biotech.

Comparison to Industry Standards

• Many early-stage biotechnology companies, similar to Xilio Therapeutics, often face challenges in maintaining Nasdaq's financial and market capitalization requirements, especially during periods of high R&D expenditure and limited revenue generation.
• Companies like Aileron Therapeutics (ALRN) and Checkpoint Therapeutics (CKPT) have also faced Nasdaq delisting notices for similar reasons (minimum bid price or market value of publicly held shares) in the past, often leading to reverse stock splits or transfers to the Nasdaq Capital Market to maintain listing.
• Maintaining a minimum stockholders' equity of $10 million is a standard requirement for the Nasdaq Global Select Market, indicating a certain level of financial stability. Falling below this threshold, as Xilio has, suggests a weaker financial position compared to more established biotech firms.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, potential loss of liquidity if transferred to a lower market, and negative impact on share price due to non-compliance.
• Investors: May view the company as higher risk, potentially impacting future investment decisions and access to capital.
• Employees: Uncertainty regarding the company's long-term stability and listing status could affect morale and retention.

Next Steps

• Submit a plan to Nasdaq by October 6, 2025, to regain compliance with the stockholders' equity requirement.
• Evaluate options to regain compliance with the $1.00 minimum bid price requirement before October 1, 2025.
• Potentially apply to transfer securities to The Nasdaq Capital Market.
• Continue evaluating available options to regain compliance with all Nasdaq listing requirements.

Key Dates

Recommendation

The company is facing two critical Nasdaq listing deficiencies: insufficient stockholders' equity and a prolonged failure to meet the minimum bid price. These issues significantly increase the risk of delisting, which would severely impact liquidity and investor confidence. Without a clear, immediate path to compliance and given the existing financial weakness, the stock presents a high-risk profile with substantial downside potential.

Keywords

Xilio Therapeutics, Nasdaq, Delisting, Stockholders' Equity, Minimum Bid Price, Compliance, 8-K Filing, Biotechnology, XLO